---------------------------------------------------------------
Mensagem enviada por "silvio dias" <[EMAIL PROTECTED]>
---------------------------------------------------------------
...
-----Mensagem Original-----
De: "Alexandre Hamam" <[EMAIL PROTECTED]>
Para: <[EMAIL PROTECTED]>
Enviada em: Segunda-feira, 29 de Janeiro de 2001 20:51
Assunto: isospaglúmico
> Silvio,
>
> Estou lhe enviando o único trabalho científico sobre o ácido isospaglumico
> para Rinite alérgica que encontrei na medline. Achei outros, mas para
> conjuntivite alérgica.
> OBS: À propósito, achei sua pergunta extremamente válida. Não achei que
você
> estava brincando quando disse "científica".
>
> Abraços,
> Alexandre Hamam
>
> --------------------------------------------------------------------------
--
> -
> Seasonal allergic rhinitis. Newer treatment approaches.
> Drugs 1993 Apr;45(4):518-27
> Horak F
>
> ENT-University Clinic, Vienna, Austria.
>
> Improved treatment approaches for seasonal allergic rhinitis are based on
> the increasing knowledge about allergic inflammation and on the improved
> efficacy of newer drugs. The current management concept includes an
> individualised composition of the different approaches including allergen
> avoidance, topical treatment and the use of systemic drugs and specific
> immunotherapy. Allergen avoidance, supported by pollen information, leads
to
> a remarkable reduction of daily challenge situations. There is an
increasing
> trend towards topical use of corticosteroids (e.g. budesonide and
> fluticasone) and mast cell stabilisers [e.g. sodium cromoglycate (cromolyn
> sodium), nedocromil and isospaglumic acid (N-acetylaspartylglutamic acid)]
> because of the potency of these drugs to impair the destructive activity
of
> allergic inflammation. Potent histamine H1-receptor antagonists (e.g.
> azelastine and levocabastine) are approved for local treatment and lead to
> prompt relief of troublesome symptoms. A new generation of orally active
> antihistamines (e.g. astemizole, cetirizine, loratadine and terfenadine)
> have tended to be called 'antiallergics' because of activity other than
> H1-blockade. Furthermore, these newer compounds are less likely to cause
> sedation. Immunotherapy is still an integrated component in the treatment
> strategy. Standardised allergen extracts of high quality raise the
treatment
> efficacy and safety. Overall, forming an individual combination of
treatment
> approaches gives the best result.
>
> --------------------------------------------------------------------------
--
> -------
>
>
...
--------------------------------------------------------------------
LISTA OTORRINO
Para sair desta lista envie uma msg para:
[EMAIL PROTECTED]
deixe o assunto em branco e no corpo da msg escreva:
unsubscribe otorrino
Moderador: [EMAIL PROTECTED]
